Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside.

摘要: Cancer is a disease caused by DNA mutations. therapies targeting defined functional mutations have shown clinical benefit. However, as 95% of the in tumour are unique to that single patient and only small number shared between patients, addressed medical need modest. A rapidly determined patient-specific mutation pattern combined with flexible mutation-targeting drug platform could generate individualised therapy, which would benefit each patient. Next-generation sequencing enables rapid identification somatic individual tumours (the mutanome). Immunoinformatics predictions immunogenicity. Mutation-targeting RNA-based vaccines can be affordably synthesised custom GMP products. Integration these cutting-edge technologies into clinically applicable process holds promise disruptive innovation benefiting cancer patients. Here, we describe our translation vaccine concept clinic trials.